Yahoo! has been so bad lately - especially the MRK board. I like using (http://Themaxgains.tech) now instead for my daily research.
W
Up again today in a red tape. Good news keeps rolling in. SGEN buyout could hurt price and earnings in short term but 2 years out it gets accretive according to recently published analysis. Long and strong! Just wish I bought more at 82.
MRK $125 min to $150 within 12 months fundamental and technical dream w a 3% yield. Beat and raise quarter powerhouse. P/E of 18-20 makes MRK a bargain sub $90 today
MRK needs some help to compete. News out today 6/4/22 (VTVT) and their TTP399 going for FDA 3 trials soon, People with Type 1 Diabetes may get an oral drug soon. MRK tried before to get in this market, MRK needs to take a look for us shareholders.
K
Merck & Company's upcoming ex-dividend date is on Jun 13, 2022. Merck & Company shareholders who own MRK stock before this date will receive Merck & Company's next dividend payment of $0.69 per share 🎉
WATCH for possible breakout above 94.37, no resistance in area just above. Type: Continuation breakout from single resistance. Target: 99.14 Stop: 91.40
C
BIG news for MRK. the stage #3 Metastasis news could be huge stock up over $100 this week
W
Article out today says MRK sniffing around Seagen...
D
Great volume today 6/24, more than 2x the three month average
Maybe Merck will have stock split. Google and Amazon are expected to split soon. I'd love it if Merck had a split.
R
Tee hee
B
MRK trading at 12x this year's earnings is far from being expensive. Over $100 soon.
T
Load up people $MRK Getting ready to take off
T
Somethings up besides the sp. opened down on 1.2 M shares now up much more at 2.3 M—-we usually don’t get this much attention
T
Huge Investor Event being held this morning, More than 80 potential oncology approvals thru 2028, This stock was listed as one to watch.👍
S
Merck benefited from that failure of the phase 3 trial for Roche’s immune checkpoint inhibitor tiragolumab failed in non-small cell lung cancer, both on the co-primary endpoint of progression-free survival (PFS).
Type: Continuation breakout from single resistance.
Target: 99.14
Stop: 91.40
https://assets.wallstreet-online.de/_media/8763/board/20220328161719-screenshot-2022-03-28-at-16-16-43-powerpoint-pres.png
####